白雲山(600332.SH):光華藥業獲磷酸氯喹片藥品補充申請批件
格隆匯2月17日丨白雲山(600332.SH)公佈,2020年2月17日,公司控股子公司廣州白雲山光華製藥股份有限公司(“光華藥業”)收到廣東省藥品監督管理局核准簽發的磷酸氯喹片《藥品補充申請批件》。
磷酸氯喹片主要用於治療對氯喹敏感的惡性瘧、間日瘧及三日瘧。並可用於瘧疾症狀的抑制性預防。也可用於治療腸外阿米巴病、結締組織病、光敏感性疾病(如日曬紅斑)等。
在國家藥品監督管理局網站查詢,磷酸氯喹片共有30個批准文號。根據米內網數據顯示,2018年,磷酸氯喹片在中國城市公立醫院、縣級公立醫院的銷售總額約為人民幣170萬元。除此之外,公司無法從公開渠道獲悉其他生產企業此藥品的生產或銷售數據。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.